Seasonal Influenza Vaccine and Protection against Pandemic (H1N1) 2009-Associated Illness among US Military Personnel
Open Access
- 19 May 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (5) , e10722
- https://doi.org/10.1371/journal.pone.0010722
Abstract
A novel A/H1N1 virus is the cause of the present influenza pandemic; vaccination is a key countermeasure, however, few data assessing prior seasonal vaccine effectiveness (VE) against the pandemic strain of H1N1 (pH1N1) virus are available. Surveillance of influenza-related medical encounter data of active duty military service members stationed in the United States during the period of April–October 2009 with comparison of pH1N1-confirmed cases and location and date-matched controls. Crude odds ratios (OR) and VE estimates for immunized versus non-immunized were calculated as well as adjusted OR (AOR) controlling for sex, age group, and history of prior influenza vaccination. Separate stratified VE analyses by vaccine type (trivalent inactivated [TIV] or live attenuated [LAIV]), age groups and hospitalization status were also performed. For the period of April 20 to October 15, 2009, a total of 1,205 cases of pH1N1-confirmed cases were reported, 966 (80%) among males and over one-half (58%) under 25 years of age. Overall VE for service members was found to be 45% (95% CI, 33 to 55%). Immunization with prior season's TIV (VE = 44%, 95% CI, 32 to 54%) as well as LAIV (VE = 24%, 95% CI, 6 to 38%) were both found to be associated with protection. Of significance, VE against a severe disease outcome was higher (VE = 62%, 95% CI, 14 to 84%) than against milder outcomes (VE = 42%, 95% CI, 29 to 53%). A moderate association with protection against clinically apparent, laboratory-confirmed Pandemic (H1N1) 2009-associated illness was found for immunization with either TIV or LAIV 2008–09 seasonal influenza vaccines. This association with protection was found to be especially apparent for severe disease as compared to milder outcome, as well as in the youngest and older populations. Prior vaccination with seasonal influenza vaccines in 2004–08 was also independently associated with protection.Keywords
This publication has 51 references indexed in Scilit:
- Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza VirusScience, 2010
- Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human populationProceedings of the National Academy of Sciences, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesNew England Journal of Medicine, 2009
- Component‐Specific Effectiveness of Trivalent Influenza Vaccine as Monitored through a Sentinel Surveillance Network in Canada, 2006–2007The Journal of Infectious Diseases, 2009
- Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)Archives of internal medicine (1960), 2008
- Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivorsNature, 2008
- Prevention of Symptomatic Seasonal Influenza in 2005–2006 by Inactivated and Live Attenuated VaccinesThe Journal of Infectious Diseases, 2008
- Rapid Decline of Influenza Vaccine–Induced Antibody in the Elderly: Is It Real, or Is It Relevant?The Journal of Infectious Diseases, 2008
- Comparative Immunogenicities of Frozen and Refrigerated Formulations of Live Attenuated Influenza Vaccine in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2007